Business

Market Movers

Eye drug could face generic rivals sooner

Allergan makes Restasis to treat chronic dry eye.

AFP

Allergan makes Restasis to treat chronic dry eye.

Advertisement

Allergan Inc.’s Restasis treatment for chronic dry eye disease could face generic competition sooner than expected, leading to downgrades by Deutsche Bank and Leerink Swann, Dow Jones reported. Sales estimates for Restasis, Allergan’s second-biggest drug, could be reduced 67 percent in 2016, Deutsche Bank said; it cut its rating to “hold.” Analysts assumed “minimal to no generic risk” for Allergan, which also makes Botox, but new FDA guidance changes the equation, the investment bank said.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com